RTOG Foundation, Inc.

Five-fraction stereotactic body radiotherapy (SBRT) showed noninferior biochemical or clinical failure rates compared to standard radiotherapy in low- to intermediate-risk localized prostate cancer patients, with 5-year freedom rates of 95.8% and 94.6% respectively. The study, PACE-B, involved 874 patients and highlighted SBRT's potential for favorable outcomes and reduced treatment fractions.

Weekly online MR-Linac adaptive radiotherapy with temozolomide reduced CTV margins and normal brain tissue exposure in high-grade glioma patients, with 4% marginal failure and 40% CTV margin reduction compared to EORTC methods. Median PFS and OS were 11.6 and 18.5 months for long-course radiotherapy, and 6.8 and 10.6 months for short-course radiotherapy, respectively.

MR-guided adaptive on-line radiation with margin reduction in high-grade glioma patients showed safety and feasibility, with marginal failure at 4% and significant CTV margin reduction. Long-course radiotherapy had median PFS of 11.6 months and OS of 18.5 months, while short-course had PFS of 6.8 months and OS of 10.6 months.

Dr. Neil Desai discussed the role of ADT and genomic risk stratification for unfavorable intermediate-risk prostate cancer at the 2024 ASTRO annual meeting, emphasizing the use of advanced risk classifiers like Decipher, Prolaris, Oncotype DX GPS, and MMAI to guide treatment decisions, including the duration of ADT and RT intensity.

Mack Roach, III, MD, FASTRO, receives ASTRO's 2024 Gold Medal Award for significant contributions to radiation oncology, particularly in prostate cancer treatment. Roach pioneered techniques like 3D conformal radiation therapy and IMRT, developed predictive models, and led phase III trials. His work on health disparities and community service further underscores his impact.